Editas Medicine (EDIT) Non-Current Debt (2024 - 2025)
Editas Medicine (EDIT) reported Non-Current Debt of $53.6 million for Q4 2025, up 2.23% year-over-year from $52.4 million in Q4 2024, and down 0.86% quarter-over-quarter from $54.1 million in Q3 2025.
Editas Medicine (EDIT) Non-Current Debt (2024 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 2 years of Non-Current Debt data on file, last reported at $53.6 million in Q4 2025.
- Non-Current Debt for Q4 2025 came in at $53.6 million, up 2.23% year-over-year; the trailing twelve-month figure through Dec 2025 was $53.6 million (up 2.23% YoY), and the FY2025 annual result was $53.6 million, up 2.23% from the prior year.
- Non-Current Debt fell to $53.6 million in Q4 2025 per EDIT's latest filing, from $54.1 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $54.1 million in Q3 2025 and troughed at $49.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 319.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | 53.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 53.61 Mn |
| Dec 31, 2025 | 53.61 Mn |
| Sep 30, 2025 | 54.07 Mn |
| Sep 30, 2025 | 54.07 Mn |
| Jun 30, 2025 | 51.67 Mn |
| Jun 30, 2025 | 51.67 Mn |
| Mar 31, 2025 | 49.58 Mn |
| Mar 31, 2025 | 49.58 Mn |
| Dec 31, 2024 | 52.43 Mn |
| Dec 31, 2024 | 52.43 Mn |